Shares of Cambrex Corporation (NYSE:CBM) have earned an average rating of “Buy” from the six ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $65.67.
A number of equities research analysts recently weighed in on CBM shares. Zacks Investment Research lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. ValuEngine lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, BidaskClub upgraded Cambrex Corporation from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/09/13/cambrex-corporation-cbm-receives-65-67-consensus-pt-from-analysts.html.
In other Cambrex Corporation news, CEO Steven M. Klosk sold 12,000 shares of the company’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $54.19, for a total value of $650,280.00. Following the sale, the chief executive officer now owns 95,328 shares in the company, valued at approximately $5,165,824.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Samantha Hanley sold 14,000 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $57.56, for a total value of $805,840.00. Following the completion of the sale, the vice president now owns 1,500 shares in the company, valued at approximately $86,340. The disclosure for this sale can be found here. Insiders sold a total of 70,656 shares of company stock worth $4,064,423 in the last quarter. Corporate insiders own 2.48% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the stock. Flinton Capital Management LLC raised its stake in Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock worth $103,000 after buying an additional 68 shares during the period. Creative Planning increased its position in shares of Cambrex Corporation by 162.6% in the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock worth $105,000 after buying an additional 1,093 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Cambrex Corporation by 9.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock worth $105,000 after buying an additional 150 shares in the last quarter. YorkBridge Wealth Partners LLC increased its position in shares of Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock worth $106,000 after buying an additional 315 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new position in shares of Cambrex Corporation during the first quarter worth about $109,000. Hedge funds and other institutional investors own 98.28% of the company’s stock.
Shares of Cambrex Corporation (NYSE CBM) traded up 2.80% during trading on Friday, hitting $51.35. 384,290 shares of the stock traded hands. The company has a market cap of $1.68 billion, a price-to-earnings ratio of 18.71 and a beta of 2.28. Cambrex Corporation has a 52 week low of $38.30 and a 52 week high of $62.95. The firm’s 50-day moving average price is $56.43 and its 200-day moving average price is $55.37.
Cambrex Corporation (NYSE:CBM) last posted its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, hitting analysts’ consensus estimates of $0.76. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The company had revenue of $134.55 million during the quarter, compared to analysts’ expectations of $136.82 million. During the same quarter in the previous year, the firm earned $0.68 EPS. Cambrex Corporation’s revenue was up 13.4% on a year-over-year basis. On average, equities research analysts anticipate that Cambrex Corporation will post $3.08 earnings per share for the current year.
About Cambrex Corporation
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.